(Q37829362)

24 August 2017

1 reference

title

Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature (English)

1 reference

adult-onset Still's disease

24 August 2017

1 reference

1 reference

Christian Dejaco

6

0 references

author name string

Rene Thonhofer

1

1 reference

24 August 2017

Manuela Hiller

2

1 reference

24 August 2017

Horst Just

3

1 reference

24 August 2017

Markus Trummer

4

1 reference

24 August 2017

Cornelia Siegel

5

1 reference

24 August 2017

language of work or name

1 reference

15 January 2011

1 reference

Rheumatology International

24 August 2017

published in

1 reference

24 August 2017

volume

31

1 reference

24 August 2017

issue

12

1 reference

24 August 2017

page(s)

1653-1656

1 reference

Fatal myocarditis in adult-onset Still disease with diffuse intravascular coagulation.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1631-Y

Decrease of proteinuria in a patient with adult-onset Still's disease and glomerulonephritis after anti-TNFalpha therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1631-Y

Rapid responses to anakinra in patients with refractory adult-onset Still's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1631-Y

Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1631-Y

Etanercept as a rescue agent in patient with adult onset Still's disease complicated with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1631-Y

Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1631-Y

Diagnosis and management of adult onset Still's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1631-Y

Defective inflammatory response in interleukin 6-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1631-Y

Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1631-Y

Macrophage activation syndrome associated with adult-onset Still's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1631-Y

Interleukin 6: a possible marker of disease activity in adult onset Still's disease

21 January 2018

1 reference

12 December 2020

Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease

1 reference

12 December 2020

Tocilizumab for multirefractory adult-onset Still's disease

1 reference

12 December 2020

Preliminary criteria for classification of adult Still's disease

1 reference

12 December 2020

The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease

1 reference

12 December 2020

Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab

1 reference

12 December 2020

10.1007/S00296-010-1631-Y

Identifiers

DOI

1 reference

release_y5zll7wftjadxneqjojsr4oz6a

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y5zll7wftjadxneqjojsr4oz6a

24 November 2022

mapped directly with Wikidata item

1 reference